These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29574070)

  • 1. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.
    Chapman MJ; Orsoni A; Robillard P; Therond P; Giral P
    J Clin Lipidol; 2018; 12(3):784-800.e4. PubMed ID: 29574070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects.
    Lassel TS; Guérin M; Auboiron S; Chapman MJ; Guy-Grand B
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):65-74. PubMed ID: 9445258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients.
    Kimak E; Bylina J; Solski J; Hałabiś M; Baranowicz-Gąszczyk I; Książek A
    Cell Biochem Biophys; 2013 Nov; 67(2):695-702. PubMed ID: 23479335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.
    Chapman MJ; Orsoni A; Tan R; Mellett NA; Nguyen A; Robillard P; Giral P; Thérond P; Meikle PJ
    J Lipid Res; 2020 Jun; 61(6):911-932. PubMed ID: 32295829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.
    Ambrosch A; Mühlen I; Kopf D; Augustin W; Dierkes J; König W; Luley C; Lehnert H
    Diabetes Care; 1998 Dec; 21(12):2077-84. PubMed ID: 9839097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.
    Guérin M; Le Goff W; Lassel TS; Van Tol A; Steiner G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2001 Feb; 21(2):282-8. PubMed ID: 11156866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.
    Adiels M; Chapman MJ; Robillard P; Krempf M; Laville M; Borén J;
    J Clin Lipidol; 2018; 12(3):810-821.e1. PubMed ID: 29753732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia.
    Guérin M; Bruckert E; Dolphin PJ; Chapman MJ
    Eur J Clin Invest; 1996 Jun; 26(6):485-94. PubMed ID: 8817163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
    Kettunen J; Holmes MV; Allara E; Anufrieva O; Ohukainen P; Oliver-Williams C; Wang Q; Tillin T; Hughes AD; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT; Salomaa V; Järvelin MR; Perola M; Davey Smith G; Chaturvedi N; Danesh J; Di Angelantonio E; Butterworth AS; Ala-Korpela M
    PLoS Biol; 2019 Dec; 17(12):e3000572. PubMed ID: 31860674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.
    Meikle PJ; Wong G; Tan R; Giral P; Robillard P; Orsoni A; Hounslow N; Magliano DJ; Shaw JE; Curran JE; Blangero J; Kingwell BA; Chapman MJ
    J Lipid Res; 2015 Dec; 56(12):2381-92. PubMed ID: 26486974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia.
    Moulin P; Appel GB; Ginsberg HN; Tall AR
    J Lipid Res; 1992 Dec; 33(12):1817-22. PubMed ID: 1479291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.